Regulation of the pro-angiogenic factor VEGF (vascular endothelial growth factor) and its receptor, VEGFR-1, as well as matrix metalloproteinases (MMPs) by estrogens, may represent one of the key molecular pathways responsible for the angiogenic effect of E2 during breast cancer development and progression [51,52]. The gene discussed is VEGFA; the disease is breast cancer.